(Q52002507)

19 April 2018

title

How is quality of life in prostate cancer patients influenced by modern treatment? The Wallenberg Symposium. (English)

1 reference

19 April 2018

1 reference

1 reference

11

1 reference

19 April 2018

Sophie D. Fosså

6

object named as

Fosså S

1 reference

19 April 2018

Altwein J

1

1 reference

19 April 2018

Ekman P

2

1 reference

19 April 2018

Barry M

3

1 reference

19 April 2018

Biermann C

4

1 reference

19 April 2018

Carlsson P

5

1 reference

19 April 2018

Kiebert G

7

1 reference

19 April 2018

Küchler T

8

1 reference

19 April 2018

McLeod D

9

1 reference

19 April 2018

Porter A

10

1 reference

19 April 2018

language of work or name

English

0 references

publication date

1 April 1997

1 reference

19 April 2018

published in

Urology

1 reference

19 April 2018

volume

49

1 reference

19 April 2018

issue

4A Suppl

1 reference

19 April 2018

page(s)

66-76

1 reference

19 April 2018

A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Recent results of management of palpable clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

The MOS short-form general health survey. Reliability and validity in a patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Influence of urological morbidity on quality of life in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Impact of anatomical radical prostatectomy on urinary continence

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

The role of radical prostatectomy in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Impact of bladder neck preservation during radical prostatectomy on continence and cancer control

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Patient-re ported complications and follow-up treatment after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Quality of life of incontinent men after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Decreased sexual capacity after external radiation therapy for prostate cancer impairs quality of life.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Waning sexual function--the most important disease-specific distress for patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Nerve sparing radical prostatectomy: a different view

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

National Patterns of Prostate Cancer Treatment by Radical Prostatectomy: Results of a Survey by the American College of Surgeons Commission on Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Anastomotic strictures following radical prostatectomy: risk factors and management

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Measurement of quality of life in localized prostatic cancer patients treated with radiotherapy. Development of a prostate cancer-specific module supplementing the EORTC QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Self-assessment questionnaire for evaluating urinary and intestinal late side effects after pelvic radiotherapy in patients with prostate cancer compared with an age-matched control population

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Quality-of-life outcomes in men treated for localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Quality of life 12 months after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Quality of life after radical retropubic prostatectomy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Bicalutamide in the treatment of advanced prostatic carcinoma: a phase II multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Patients' choice of treatment in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

Quality of life after palliative radiotherapy in patients with hormone‐resistant prostate cancer: single institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980325-2

7 January 2021

10.1016/S0090-4295(99)80325-2

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018